IQVIA Holdings (IQV) 10-K Summary — Year Ended Dec 31, 2025
IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence, using AI and data analytics to support life sciences and healthcare clients. The company reported revenue growth over the recent fiscal period, with operating income, net income, and operating cash flow all positive.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence, using AI and data analytics to support life sciences and healthcare clients. The company reported revenue growth over the recent fiscal period, with operating income, net income, and operating cash flow all positive.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$16.3B
Revenue reported for the fiscal year.
Operating income
$2.2B
Income from operations reported for the year.
Net income
$1.4B
Net income reported for the year.
Operating cash flow
$2.7B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $14.4B | +3.9% |
| Dec 31, 2023 | $15B | +4.0% |
| Dec 31, 2024 | $15.4B | +2.8% |
| Dec 31, 2025 | $16.3B | +5.9% |
Business overview
IQVIA is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. Its portfolio is powered by IQVIA Connected Intelligence, using healthcare-grade AI, advanced analytics, and high-quality health data to deliver actionable insights. The company employs about 93,000 people in over 100 countries, focusing on accelerating the development and commercialization of innovative medical treatments while protecting patient privacy.
Financial performance
Revenue increased over the periods shown, reaching the reported amount. Operating income, net income, and operating cash flow were all reported at positive levels. The trend indicates consistent revenue growth across the years presented.
Material risks
The filing lists a risk factors section and contains forward-looking statements, but the supplied context does not include specific descriptions of those risks. No material risk details were provided in the available excerpts.
Liquidity and capital
The company has a long-standing stock repurchase program that has been authorized and increased several times, including a recent increase. The program does not obligate the company to repurchase any specific amount, and repurchase timing and amount depend on market conditions and corporate requirements.
What to watch
Monitor the trend of revenue growth, which has shown consistent increases over the reported periods, to see if it continues in the next filing.